7250 Effects of Romosozumab According To Prior Anti-Resorptive Treatments In Korean Postmenopausal Women From The Real-World Data: A Multi-Center Retrospective Study

Abstract

Abstract Disclosure: Y. Kim: None. S. Ahn: None. S. Lee: None. S. Lee: None. H. Kim: None. S. Hong: None. Objectives: This study investigated the effects of romosozumab in Korean postmenopausal women based on their prior anti-resorptive treatments for osteoporosis from real-world data. Methods: A retrospective analysis of 145 postmenopausal women (66 drug-naïve [45.5%], 27 prior bisphosphonate [BP, 18.6%], 11 prior selective estrogen receptor modulator [SERM, 7.6%], and 41 prior denosumab [DMAB, 28.3%] groups) who received a 12-month romosozumab treatment between March 2020 and June 2023 at four hospitals in Korea was conducted. Changes in bone mineral densities (BMDs) at the lumbar spine (LS), total hip (TH), and femoral neck (FN), as well as bone turnover markers (C-telopeptide [CTX] and N-terminal type I procollagen propeptide [P1NP]), were evaluated. Results: Significant differences in BMD changes at all skeletal sites were observed between the groups (LS, TH, and FN: P<0.001, P<0.001, and P=0.018, respectively). Especially, the drug-naïve group showed a significantly greater increase in BMD change than the prior DMAB group at LS (17.5% vs. 6.5%, P<0.001), TH (4.8% vs. -0.2%, P<0.001), and FN (5.7% vs. 1.4%, P=0.015). The highest levels of P1NP were observed in the drug-naïve, prior BP, and prior SERM groups after one month of romosozumab treatment, while it was observed after six months in the prior DMAB group. Additionally, CTX levels decreased in the drug-naïve, prior BP, and prior SERM groups during romosozumab treatment, while an increase was observed in the prior DMAB group. Conclusion: The efficacy of romosozumab treatment is influenced by prior anti-resorptive therapies. Further investigation is necessary to develop personalized strategies for optimizing romosozumab's effectiveness based on prior osteoporosis medications, especially in prior DMAB group. Presentation: 6/3/2024